T‐cell response after first dose of BNT162b2 SARS‐CoV‐2 vaccine among healthcare workers with previous infection or cross‐reactive immunity-Reference-Cited by-同舟云学术

T‐cell response after first dose of BNT162b2 SARS‐CoV‐2 vaccine among healthcare workers with previous infection or cross‐reactive immunity

Published:2021-01 Issue:9 Volume:10 Page:
ISSN:2050-0068
Container-title:Clinical & Translational Immunology
language:en
Short-container-title:Clin Transl Immunol

Author:

Casado Jose L¹^ORCID,Haemmerle Johannes²,Vizcarra Pilar¹,Rodriguez‐Dominguez Mario³,Velasco Tamara¹,Velasco Hector⁴,Centenera Elena¹,Romero‐Hernandez Beatriz³,Fernandez‐Escribano Marina²,Vallejo Alejandro¹⁴

Affiliation:

1. Department of Infectious Diseases Hospital Universitario Ramón y Cajal Madrid Spain

2. Department of Prevention of Occupational Risks Hospital Universitario Ramón y Cajal Madrid Spain

3. Department of Microbiology IRYCIS, Instituto Ramón y Cajal de Investigaciones Sanitarias CIBERESP Hospital Universitario Ramón y Cajal Madrid Spain

4. Laboratory of Immunovirology IRYCIS, Instituto Ramón y Cajal de Investigaciones Sanitarias CIBERESP Hospital Universitario Ramón y Cajal Madrid Spain

Funder

Instituto de Salud Carlos III

Publisher

Wiley

Subject

General Nursing,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cti2.1341

Reference22 articles.

1. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

2. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

3. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting